NCT03051035: First-in-Human Study of KO-947 in Non-Hematological Malignancies

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: RAS
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1
Drug Category: Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Patients must tumors that express a BRAF, KRAS, NRAS or HR+AS mutation(s)
Exclusions: Patients with known uncontrolled unstable brain, leptomeningeal or epidural metastases- see trial for details

Comments are closed.

Up ↑